NASDAQ : PBYI
Puma Biotechnology, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 10.54 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 544.08M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 538.91M |
| Enterprise Value | 449.83M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 51.62M |
| Shares Outstanding | 51.62M |
| Shares Change (YoY) | +3.62% |
| Shares Change (QoQ) | +3.44% |
| Owned by Insiders (%) | 13.84% |
| Owned by Institutions (%) | 67.80% |
| Float | 40.34M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 20.73 |
| Forward PE | n/a |
| PS Ratio | 2.33 |
| Forward PS | 4.32 |
| PB Ratio | 3.85 |
| P/TBV Ratio | 5.28 |
| P/FCF Ratio | 13.09 |
| P/OCF Ratio | 13.10 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 16.84 |
| EV / Sales | 1.95 |
| EV / EBITDA | 11.21 |
| EV / EBIT | 14.78 |
| EV / FCF | 10.93 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.91 |
| Quick Ratio | 2.57 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.11 |
| Debt / FCF | 0.12 |
| Interest Coverage | 8.65 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 21.97% |
| Return on Assets (ROA) | 9.81% |
| Return on Invested Capital (ROIC) | 56.55% |
| Return on Capital Employed (ROCE) | 21.30% |
| Weighted Average Cost of Capital (WACC) | 11.36% |
| Revenue Per Employee | $1.29M |
| Profits Per Employee | $149,263 |
| Employee Count | 179 |
| Asset Turnover | 1.19 |
| Inventory Turnover | 5.31 |
Taxes
| Measure | Value |
|---|
| Income Tax | 4.45M |
| Effective Tax Rate | 14.28% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.21 |
| 52-Week Price Change | +102.33% |
| 50-Day Moving Average | 9.82 |
| 200-Day Moving Average | 7.91 |
| Relative Strength Index (RSI) | 52.91 |
| Average Volume (20 Days) | 354,020 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 4.54M |
| Short Previous Month | 4.26M |
| Short % of Shares Out | 8.80% |
| Short % of Float | 11.25% |
| Short Ratio (days to cover) | 13.75 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 231.24M |
| Gross Profit | 173.05M |
| Operating Income | 30.44M |
| Pretax Income | 31.17M |
| Net Income | 26.72M |
| EBITDA | 40.12M |
| EBIT | 30.44M |
| Earnings Per Share (EPS) | $0.50 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 93.90M |
| Total Debt | 4.82M |
| Net Cash | 89.09M |
| Net Cash Per Share | $1.73 |
| Equity (Book Value) | 138.54M |
| Book Value Per Share | 2.71 |
| Working Capital | 95.25M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 41.15M |
| Capital Expenditures | 10,000 |
| Depreciation & Amortization | 9.68M |
| Net Borrowing | -44.45M |
| Free Cash Flow | 41.16M |
| FCF Per Share | $0.80 |
Margins
| Measure | Value |
|---|
| Gross Margin | 74.83% |
| Operating Margin | 13.16% |
| Pretax Margin | 13.48% |
| Profit Margin | 11.55% |
| EBITDA Margin | 17.35% |
| EBIT Margin | 13.16% |
| FCF Margin | 17.80% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.62% |
| Shareholder Yield | -3.62% |
| Earnings Yield | 4.82% |
| FCF Yield | 7.64% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 0.24% |
| EPS Growth Forecast (3Y) | -26.32% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -3.73 |
| Piotroski F-Score | 7 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |